ORIGINAL ARTICLE
Efficacy of Subcutaneous, Sublingual and Oral Immunotherapy for Allergens: A Comparative Study
Maria Zofia Lisiecka,
Corresponding Author
Maria Zofia Lisiecka
Department of Allergology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
Correspondence:
Maria Zofia Lisiecka ([email protected])
Search for more papers by this authorMaria Zofia Lisiecka,
Corresponding Author
Maria Zofia Lisiecka
Department of Allergology, National Medical Institute of the Ministry of the Interior and Administration, Warsaw, Poland
Correspondence:
Maria Zofia Lisiecka ([email protected])
Search for more papers by this authorABSTRACT
The purpose of this study was to compare the efficacy and safety of subcutaneous, sublingual, oral specific immunotherapy in patients who suffer from allergic conditions to pollen from trees, grasses and weeds, house dust mites and Alternaria alternata spores. A literature search was performed separately for each type of allergen and each administration route of the drug. As a result, it was found that all administration routes were quite effective. However, each type of immunotherapy was most effective for certain allergens. Subcutaneous and sublingual immunotherapy have proven effective for aeroallergens such as pollen from grass, trees, weeds and house dust mites. Despite this, subcutaneous immunotherapy had a number of disadvantages in the form of the duration of treatment and a greater prevalence of side effects. Some authors suggest that for allergies to house dust mites, the most effective method of immunotherapy was the subcutaneous method of administration, compared with sublingual and nasal. Sublingual therapy was safe enough for all types of allergens under study, however, to achieve the same effect as the subcutaneous method of administration. In addition, oral immunotherapy has been shown to be effective for food allergies with obvious symptoms of gastrointestinal disorders. In addition, oral immunotherapy is the only approved treatment for allergies in the elderly, due to the low risk of side effects. The time-accelerated and dosage-enhanced immunotherapy was also effective and safe. These data prove the effectiveness and safety of each administration route of specific allergens for specific immunotherapy in patients suffering from allergic rhinitis, bronchial asthma and even atopic dermatitis.
Conflicts of Interest
The author declares no conflicts of interest.
Open Research
Data Availability Statement
The data that support the findings of this study are available from the corresponding author upon reasonable request.
References
- 1 D. Larenas-Linnemann, “Allergen Immunotherapy: An Update on Protocols of Administration,” Current Opinion in Allergy and Clinical Immunology 15, no. 6 (2015): 556–567, https://doi.org/10.1097/ACI.0000000000000220.
- 2 G. F. Parisi, S. Leonardi, G. Ciprandi, et al., “Cetirizine Use in Childhood: An Update of a Friendly 30-Year Drug,” Clinical and Molecular Allergy 18, no. 1 (2020): 2, https://doi.org/10.1186/s12948-020-00118-5.
- 3 I. Hartmane, I. Ivdra, I. Mikaþâns, and V. Bondare-Ansberga, “Correlation of Immunological and Clinical Changes in Psoriasis Patients Treated With Tumour Necrosis Factor-Alpha (TNF-α) Blocking Biologic Drugs: One-Year Dynamic Observation,” Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences 75, no. 5 (2021): 357–363, https://doi.org/10.2478/prolas-2021-0052.
- 4 G. F. Pavón-Romero, M. I. Parra-Vargas, F. Ramírez-Jiménez, E. Melgoza-Ruiz, N. H. Serrano-Pérez, and L. M. Teran, “Allergen Immunotherapy: Current and Future Trends,” Cells 11, no. 2 (2022): 212, https://doi.org/10.3390/cells11020212.
- 5 M. Penagos and S. R. Durham, “Long-Term Efficacy of the Sublingual and Subcutaneous Routes in Allergen Immunotherapy,” Allergy and Asthma Proceedings 43, no. 4 (2022): 292–298, https://doi.org/10.2500/aap.2022.43.220026.
- 6 M. Contoli, C. Porsbjerg, S. Buchs, J. R. Larsen, N. Freemantle, and B. Fritzsching, “Real-World, Long-Term Effectiveness of Allergy Immunotherapy in Allergic Rhinitis: Subgroup Analyses of the REACT Study,” Journal of Allergy and Clinical Immunology 152, no. 2 (2023): 445–452.e4, https://doi.org/10.1016/j.jaci.2023.02.024.
- 7
G. Scadding, “Real World Evidence of Long-Term Benefits From Allergen-Specific Immunotherapy (AIT),” Lancet Regional Health—Europe 13 (2021): 100283, https://doi.org/10.1016/j.lanepe.2021.100283.
10.1016/j.lanepe.2021.100283 Google Scholar
- 8 C. Vogelberg, B. Brüggenjürgen, H. Richter, and M. Jutel, “Real-World Adherence and Evidence of Subcutaneous and Sublingual Immunotherapy in Grass and Tree Pollen-Induced Allergic Rhinitis and Asthma,” Patient Preference and Adherence 14 (2020): 817–827, https://doi.org/10.2147/PPA.S242957.
- 9 K. Patel, N. Gupta, B. J. Prajapati, A. Prajapati, S. Sharma, and D. Rathava, “Study on Effects of Sublingual Immunotherapy in Allergic Rhinitis Patients,” Indian Journal of Otolaryngology and Head & Neck Surgery 75, no. Suppl 1 (2023): 804–808, https://doi.org/10.1007/s12070-022-03366-w.
- 10 N. Wyrzykowska, M. Czarnecka-Operacz, and Z. Adamski, “Long-Term Efficacy of Allergen Specific Immunotherapy in Atopic Dermatitis Patients in Relation to Quality of Life,” European Annals of Allergy and Clinical Immunology 47, no. 1 (2015): 5–9.
- 11 R.-B. Tang, “House Dust Mite-Specific Immunotherapy Alters the Natural Course of Atopic March,” Journal of the Chinese Medical Association 83, no. 2 (2020): 109–112, https://doi.org/10.1097/JCMA.0000000000000231.
- 12 I. Stelmach, A. Sobocińska, P. Majak, K. Smejda, J. Jerzyńska, and W. Stelmach, “Comparison of the Long-Term Efficacy of 3- and 5-Year House Dust Mite Allergen Immunotherapy,” Annals of Allergy, Asthma & Immunology 109, no. 4 (2012): 274–278, https://doi.org/10.1016/j.anai.2012.07.015.
- 13 B. Gutarowska, M. Wiszniewska, J. Walusiak, M. Piotrowska, C. Pałczyński, and Z. Zakowska, “Exposure to Moulds in Flats and the Prevalence of Allergic Diseases—Preliminary Study,” Polish Journal of Microbiology 54, no. Suppl (2005): 13–20.
- 14 P. Kuna, J. Kaczmarek, and M. Kupczyk, “Efficacy and Safety of Immunotherapy for Allergies to Alternaria alternata in Children,” Journal of Allergy and Clinical Immunology 127, no. 2 (2011): 502–508, https://doi.org/10.1016/j.jaci.2010.11.036.
- 15 P. G. Cetinkaya, M. Kahveci, S. Esenboğa, et al., “Systemic and Large Local Reactions During Subcutaneous Grass Pollen Immunotherapy in Children,” Pediatric Allergy and Immunology 31, no. 6 (2020): 643–650, https://doi.org/10.1111/pai.13261.
- 16 P. J. de Kam, S. Zielen, J. A. Bernstein, et al., “Short-Course Subcutaneous Treatment With PQ Grass Strongly Improves Symptom and Medication Scores in Grass Allergy,” Allergy 78, no. 10 (2023): 2756–2766, https://doi.org/10.1111/all.15788.
- 17 N. Bothra, N. Gupta, R. Nowak, and M. J. Ali, “The Use of Anterograde Percutaneous Transluminal Coronary Angioplasty Balloons in Congenital Nasolacrimal Duct Obstruction: A Cost-Effective Alternative to the Traditional Dacryoplasty Balloons,” Ophthalmic Plastic and Reconstructive Surgery 36, no. 3 (2020): 302–304, https://doi.org/10.1097/IOP.0000000000001558.
- 18 J. Yang and S. Lei, “Efficacy and Safety of Sublingual Versus Subcutaneous Immunotherapy in Children With Allergic Rhinitis: A Systematic Review and Meta-Analysis,” Frontiers in Immunology 14 (2023): 1274241, https://doi.org/10.3389/fimmu.2023.1274241.
- 19 D. Dmytriiev, O. Nazarchuk, M. Faustova, et al., “Local Anesthetics Contributing the Struggling Biofilm-Forming Activity of s. Aureus Colonizing Surfaces of Venous Catheters,” Multicentrer Clinical Trial. Lek Obz 70, no. 1 (2021): 21–24.
- 20 Z. Ji and F. Jiang, “Efficacy and Safety of Sublingual Immunotherapy for Allergic Rhinitis: A Network Meta-Analysis,” Frontiers in Immunology 14 (2023): 1144816, https://doi.org/10.3389/fimmu.2023.1144816.
- 21 D. Boldovjáková, S. Cordoni, C. J. Fraser, et al., “Sublingual Immunotherapy vs Placebo in the Management of Grass Pollen-Induced Allergic Rhinitis in Adults: A Systematic Review and Meta-Analysis,” Clinical Otolaryngology 46, no. 1 (2020): 52–59, https://doi.org/10.1111/coa.13651.
- 22 F. Furci and L. Ricciardi, “Plant Food Allergy Improvement After Grass Pollen Sublingual Immunotherapy: A Case Series,” Pathogens 10, no. 11 (2021): 1412, https://doi.org/10.3390/pathogens10111412.
- 23
A. S. Turmagambetova, N. S. Sokolova, A. P. Bogoyavlenskiy, et al., “New Functionally-Enhanced Soy Proteins as Food Ingredients With Anti-Viral Activity,” Virus Diseases 26, no. 3 (2015): 123–132, https://doi.org/10.1007/s13337-015-0268-6.
10.1007/s13337?015?0268?6 Google Scholar
- 24 L. González-Bravo, J. L. García, M. Privitera, and A. Rosado, “Off-Label Use of Oral Immunotherapy for Rhinoconjunctivitis and Asthma due to Grass Pollen: A Safe and Effective Alternative in Patients Over 65 Years Old: A Series of Case Reports,” Current Drug Safety 18, no. 4 (2023): 599–602, https://doi.org/10.2174/1574886317666221010092132.
- 25 R. Nowak, M. Rekas, and M. J. Ali, “Long-Term Quality of Life in Patients Following Minimally Invasive Conjunctivodacryocystorhinostomy With StopLoss Jones Tube,” Ophthalmic Plastic & Reconstructive Surgery 38, no. 2 (2022): 170–175, https://doi.org/10.1097/IOP.0000000000002017.
- 26 O. Nazarchuk, D. Dmyrtriiev, Y. Babina, M. Faustova, and V. Burkot, “Research of the Activity of Local Anesthetics and Antiseptics Regarding Clinical Isolates of Acinetobacter baumannii as Pathogens of Postoperative Infectious Complications,” Acta Bio-Medica 93, no. 1 (2022): e2022003.
- 27 S. Nevot-Falcó, E. Gonzalez Mancebo, A. Martorell, et al., “Safety and Effectiveness of a Single Multiallergen Subcutaneous Immunotherapy in Polyallergic Patients,” International Archives of Allergy and Immunology 182, no. 12 (2021): 1226–1230, https://doi.org/10.1159/000517473.
- 28
G. M. Traina, A. Martelli, S. Barberi, et al., “Evaluation of Safety and Tolerability of a Rush Up-Dosing Allergen-Specific Immunotherapy With Grass Pollen, Birch, Hazel, and Alder Allergoid in Children With Allergic Rhinoconjunctivitis, With or Without Asthma,” Acta Bio-Medica 92, no. 1 (2021): e2021037, https://doi.org/10.23750/abm.v92i1.9096.
10.23750/abm.v92i1.9096 Google Scholar
- 29 M. Jutel, M. Bartkowiak-Emeryk, A. Bręborowicz, et al., “Sublingual Immunotherapy (SLIT)—Indications, Mechanism, and Efficacy: Position Paper Prepared by the Section of Immunotherapy, Polish Society of Allergy,” Annals of Agricultural and Environmental Medicine 23, no. 1 (2016): 44–53, https://doi.org/10.5604/12321966.1196851.
- 30 H. Nolte, S. Waserman, A. K. Ellis, T. Biedermann, and P. A. Würtzen, “Treatment Effect of the Tree Pollen SLIT-Tablet on Allergic Rhinoconjunctivitis During Oak Pollen Season,” Journal of Allergy and Clinical Immunology. In Practice 9, no. 5 (2021): 1871–1878, https://doi.org/10.1016/j.jaip.2021.01.035.
- 31 C. Owenier, C. Barnowski, M. Y. D. Leineweber, M. Verhagen, and A. Distler, “Tolerability and Safety of Sublingual Immunotherapy in Patients With Tree Pollen Allergy in Daily Practice—An Open, Prospective, Non-Interventional Study,” Journal of Clinical Medicine 12, no. 17 (2023): 5517, https://doi.org/10.3390/jcm12175517.
- 32 M. J. Mäkelä, P. Gyllfors, E. Valovirta, et al., “Immunotherapy With the SQ Tree SLIT-Tablet in Adults and Adolescents With Allergic Rhinoconjunctivitis,” Clinical Therapeutics 40, no. 4 (2018): 574–586, https://doi.org/10.1016/j.clinthera.2018.02.012.
- 33
E. T. Topchubaeva, Z. B. Imetova, A. K. Turusbekova, B. O. Abdurahmanov, and R. K. Kalmatov, “Respiratory Tract Disorders Associated With Changes of the Mucous Membrane in Workers Often Exposed to Pathological and Toxic Factors,” Journal of Environmental Treatment Techniques 8, no. 4 (2020): 1581–1585, https://doi.org/10.47277/JETT/1585.
10.47277/JETT/1585 Google Scholar
- 34 T. Biedermann, P. Couroux, T. M. Greve, and M. Mäkelä, “Safety of the Standardized Quality Tree Sublingual Immunotherapy Tablet: Pooled Safety Analysis of Clinical Trials,” Allergy 76, no. 12 (2021): 3733–3742, https://doi.org/10.1111/all.14882.
- 35 E. Taudorf, L. C. Laursen, A. Lanner, et al., “Oral Immunotherapy in Birch Pollen Hay Fever,” Journal of Allergy and Clinical Immunology 80, no. 2 (1987): 153–161, https://doi.org/10.1016/0091-6749(87)90124-2.
- 36 M. Tizro, R. Farid Hosseini, M. Khoshkhui, et al., “Evaluation of Subcutaneous Rush Immunotherapy Effectiveness in Perennial Allergic Rhinitis After a Year From Treatment,” Iranian Journal of Otorhinolaryngology 31, no. 104 (2019): 135–139, https://pubmed.ncbi.nlm.nih.gov/31223591/.
- 37 S. Albuhairi, T. Sare, P. Lakin, et al., “Systemic Reactions in Pediatric Patients Receiving Standardized Allergen Subcutaneous Immunotherapy With and Without Seasonal Dose Adjustment,” Journal of Allergy and Clinical Immunology. In Practice 6, no. 5 (2018): 1711–1716, https://doi.org/10.1016/j.jaip.2017.11.040.
- 38 Ç. Şükrü, C. Yakup, Ç. Fatih, O. Gökhan, and S. Nihat, “The Effect of Allergen Immunotherapy on the Development of New Sensitization in Children,” Turkish Archives of Pediatrics 56, no. 4 (2021): 374–379, https://doi.org/10.5152/TurkArchPediatr.2021.20133.
- 39 L. Li and K. Guan, “Effect on Quality of Life of the Mixed House Dust Mite/Weed Pollen Extract Immunotherapy,” Asia Pacific Allergy 6, no. 3 (2016): 168–173, https://doi.org/10.5415/apallergy.2016.6.3.168.
- 40 P. Moingeon and L. Mascarell, “Differences and Similarities Between Sublingual Immunotherapy of Allergy and Oral Tolerance,” Seminars in Immunology 30 (2017): 52–60, https://doi.org/10.1016/j.smim.2017.07.003.
- 41 L. Yang, Y. Yang, Q. Xu, et al., “Specific IgE and IgG4 Profiles of House Dust Mite Components in Allergen-Specific Immunotherapy,” Frontiers in Immunology 12 (2022): 786738, https://doi.org/10.3389/fimmu.2021.786738.
- 42 X. Yuan, S. Xie, L. Meng, et al., “Does Skin Prick Test Response Intensity Predict Symptom Severity and Efficacy of Subcutaneous Immunotherapy in Allergic Rhinitis?,” European Archives of Oto-Rhino-Laryngology 281, no. 2 (2024): 767–774, https://doi.org/10.1007/s00405-023-08220-5.
- 43 A. Bożek, K. Kołodziejczyk, R. Kozłowska, and G. W. Canonica, “Evidence of the Efficacy and Safety of House Dust Mite Subcutaneous Immunotherapy in Elderly Allergic Rhinitis Patients: A Randomized, Double-Blind Placebo-Controlled Trial,” Clinical and Translational Allergy 7 (2017): 43, https://doi.org/10.1186/s13601-017-0180-9.
- 44 J. C. Virchow, V. Backer, P. Kuna, et al., “Efficacy of a House Dust Mite Sublingual Allergen Immunotherapy Tablet in Adults With Allergic Asthma: A Randomized Clinical Trial,” Journal of the American Medical Association 315, no. 16 (2016): 1715–1725, https://doi.org/10.1001/jama.2016.3964.
- 45 A. Bozek, L. Starczewska-Dymek, and J. Jarzab, “Prolonged Effect of Allergen Sublingual Immunotherapy for House Dust Mites in Elderly Patients,” Annals of Allergy, Asthma & Immunology 119, no. 1 (2017): 77–82, https://doi.org/10.1016/j.anai.2017.05.012.
- 46
A. Bogacz-Piaseczyńska and A. Bożek, “The Effectiveness of Allergen Immunotherapy in Adult Patients With Atopic Dermatitis Allergic to House Dust Mites,” Medicina 59, no. 1 (2023): 15, https://doi.org/10.3390/medicina59010015.
10.3390/medicina59010015 Google Scholar
- 47 I. Piazza and N. Bizzaro, “Humoral Response to Subcutaneous, Oral, and Nasal Immunotherapy for Allergic Rhinitis due to Dermatophagoides Pteronyssinus,” Annals of Allergy 71, no. 5 (1993): 461–469, https://pubmed.ncbi.nlm.nih.gov/7755664/.
- 48 L. Zapatero, A. Martínez-Cañavate, J. M. Lucas, et al., “Clinical Evolution of Patients With Respiratory Allergic Disease due to Sensitisation to Alternaria alternata Being Treated With Subcutaneous Immunotherapy,” Allergologia et Immunopathologia 39, no. 2 (2011): 79–84, https://doi.org/10.1016/j.aller.2010.03.011.
- 49 G. Brindisi, A. Gori, C. Anania, et al., “Subcutaneous Immunotherapy (SCIT) With the New Polymerized Molecular Allergoid Alt a1: A Pilot Study in Children With Allergic Rhinitis Sensitized to Alternaria alternata ,” Journal of Clinical Medicine 12, no. 13 (2023): 4327, https://doi.org/10.3390/jcm12134327.
- 50 A. I. Tabar, L. Prieto, P. Alba, et al., “Double-Blind, Randomized, Placebo-Controlled Trial of Allergen-Specific Immunotherapy With the Major Allergen Alt a 1,” Journal of Allergy and Clinical Immunology 144, no. 1 (2019): 216–223, https://doi.org/10.1016/j.jaci.2019.02.029.
- 51 M. Pozzan and M. Milani, “Efficacy of Sublingual Specific Immunotherapy in Patients With Respiratory Allergy to Alternaria alternata : A Randomised, Assessor-Blinded, Patient-Reported Outcome, Controlled 3-Year Trial,” Current Medical Research and Opinion 26, no. 12 (2010): 2801–2806, https://doi.org/10.1185/03007995.2010.53220.
- 52 A. Bongiovanni, G. F. Parisi, M. G. Scuderi, et al., “Gastroesophageal Reflux and Respiratory Diseases: Does a Real Link Exist?,” Minerva Pediatrica 71, no. 6 (2019): 515–523, https://doi.org/10.23736/S0026-4946.19.05531-2.
- 53 A. Criado Molina, F. Guerra Pasadas, J. C. Daza Muñoz, et al., “Immunotherapy With an Oral Alternaria Extract in Childhood Asthma. Clinical Safety and Efficacy and Effects on In Vivo and In Vitro Parameters,” Allergologia et Immunopathologia 30, no. 6 (2002): 319–330, https://doi.org/10.1016/s0301-0546(02)79147-7.
- 54 A. I. Tabar, M. T. Lizaso, B. E. García, et al., “Double-Blind, Placebo-Controlled Study of Alternaria alternata Immunotherapy: Clinical Efficacy and Safety,” Pediatric Allergy and Immunology 19, no. 1 (2008): 67–75, https://doi.org/10.1111/j.1399-3038.2007.00589.x.
- 55 L. Hesse, N. van Ieperen, A. H. Petersen, J. N. G. Oude Elberink, A. J. M. van Oosterhout, and M. C. Nawijn, “High Dose Vitamin D3 Empowers Effects of Subcutaneous Immunotherapy in a Grass Pollen-Driven Mouse Model of Asthma,” Scientific Reports 10 (2020): 20876, https://doi.org/10.1038/s41598-020-77947-6.
- 56 J. Liu, J. Li, and J. Yin, “Changes of Allergic Inflammation and Immunological Parameters After Alt a 1 and A. alternata Immunotherapy in Mice,” World Allergy Organization Journal 16, no. 8 (2023): 100807, https://doi.org/10.1016/j.waojou.2023.100807.
- 57 Y. Zhai, P. Zheng, B. Sun, J. Li, and B. Wang, “Allergen-Specific Immunotherapy With Alutard SQ Improves Allergic Inflammation in House-Dust Mites-Induced Allergic Asthma Rats Through Inactivation of the HMGB1/TLR4/NF-κB Pathway,” Journal of Thoracic Disease 15, no. 1 (2023): 77–89, https://doi.org/10.21037/jtd-22-715.
- 58 W. Ishida, T. Kishimoto, F. Takaiwa, and K. Fukuda, “Prophylactic and Therapeutic Effects of Oral Immunotherapy on Birch Pollen-Induced Allergic Conjunctivitis in Mice With a Rice-Based Edible Vaccine Expressing a Hypoallergenic Birch Pollen Allergen,” Cells 10, no. 12 (2021): 3361, https://doi.org/10.3390/cells10123361.
- 59 M. Tankersley, T. Winders, M. Aagren, et al., “Preference for Immunotherapy With Tablets by People With Allergic Rhinitis,” Patient Preference and Adherence 15 (2021): 2539–2549, https://doi.org/10.2147/PPA.S338337.
- 60 R. S. Rahman and D. R. Wesemann, “Immunology of Allergen Immunotherapy,” Immunotherapy Advances 2, no. 1 (2022): ltac022, https://doi.org/10.1093/immadv/ltac022.
- 61
E. Dmitrova, O. Smiyan, V. Holubnycha, et al., “State of Immunity in Preschoolers With Acute Respiratory Viral Infections Associated With Adenoid Vegetations,” Proceedings of the Shevchenko Scientific Society. Medical Sciences 65, no. 2 (2021): 174–180, https://doi.org/10.25040/NTSH2021.02.17.
10.25040/ntsh2021.02.17 Google Scholar
- 62 V. P. López Couso, M. Tortajada-Girbés, D. Rodriguez Gil, J. Martínez Quesada, and P. R. Palacios, “Fungi Sensitization in Spain: Importance of the Alternaria alternata Species and Its Major Allergen Alt a 1 in the Allergenicity,” Journal of Fungi (Basel) 7, no. 8 (2021): 631, https://doi.org/10.3390/jof7080631.
- 63 T. M. Buckey, P. K. Gleeson, C. M. Curley, S. F. Feldman, A. J. Apter, and O. O. Fadugba, “Demographic Characteristics Associated With a Penicillin Allergy Label During Pregnancy,” Frontiers in Allergy 5 (2024): 1511392, https://doi.org/10.3389/falgy.2024.1511392.
- 64 A. Telia, “Dominant Aeroallergens and Demographic Factors Associated With Asthma and Allergic Rhinitis,” Georgian Medical News 321 (2021): 168–173.
- 65 P. S. Creticos, F. E. Gunaydin, H. Nolte, C. Damask, and S. R. Durham, “Allergen Immunotherapy: The Evidence Supporting the Efficacy and Safety of Subcutaneous Immunotherapy and Sublingual Forms of Immunotherapy for Allergic Rhinitis/Conjunctivitis and Asthma,” Journal of Allergy and Clinical Immunology. In Practice 12, no. 6 (2024): 1415–1427, https://doi.org/10.1016/j.jaip.2024.04.034.
Citing Literature
